Fonti R, Del Vecchio S, Zannetti A, De Renzo A, Di Gennaro F, Catalano L, Califano C, Pace L, Rotoli B, Salvatore M
Medicina Nucleare, Facoltà di Medicine, Università Federico II, Naples, Italy.
Eur J Nucl Med. 2001 Feb;28(2):214-20. doi: 10.1007/s002590000434.
In a previous study, we showed the ability of technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) scan to identify active disease in patients with multiple myeloma (Eur J Nucl Med 1998; 25: 714-720). In particular, a semiquantitative score of the extension and intensity of bone marrow uptake was derived and correlated with both the clinical status of the disease and plasma cell bone marrow infiltration. In order to estimate quantitatively 99mTc-MIBI bone marrow uptake and to verify the intracellular localization of the tracer, bone marrow samples obtained from 24 multiple myeloma patients, three patients with monoclonal gammopathy of undetermined significance (MGUS) and two healthy donors were studied for in vitro uptake. After centrifugation over Ficoll-Hypaque gradient, cell suspensions were incubated with 99mTc-MIBI and the uptake was expressed as the percentage of radioactivity specifically retained within the cells. The cellular localization of the tracer was assessed by micro-autoradiography. Twenty-two out of 27 patients underwent 99mTc-MIBI scan within a week of bone marrow sampling. Whole-body images were obtained 10 min after intravenous injection of 555 MBq of the tracer; the extension and intensity of 99mTc-MIBI uptake were graded using the semiquantitative score. A statistically significant correlation was found between in vitro uptake of 99mTc-MIBI and both plasma cell infiltration (Pearson's coefficient of correlation r=0.69, P<0.0001) and in vivo score (Spearman rank correlation coefficient r=0.60, P<0.01). No specific tracer uptake was found in bone marrow samples obtained from the two healthy donors. Micro-autoradiography showed localization of 99mTc-MIBI inside the plasma cells infiltrating the bone marrow. Therefore, our findings show that the degree of tracer uptake both in vitro and in vivo is related to the percentage of infiltrating plasma cells which accumulate the tracer in their inner compartments.
在之前的一项研究中,我们展示了锝-99m甲氧基异丁基异腈(99mTc-MIBI)扫描识别多发性骨髓瘤患者活动性疾病的能力(《欧洲核医学杂志》1998年;25:714 - 720)。特别是,得出了骨髓摄取范围和强度的半定量评分,并将其与疾病的临床状态及浆细胞骨髓浸润情况相关联。为了定量估计99mTc-MIBI骨髓摄取并验证示踪剂的细胞内定位,对从24例多发性骨髓瘤患者、3例意义未明的单克隆丙种球蛋白病(MGUS)患者以及2名健康供体获取的骨髓样本进行了体外摄取研究。在Ficoll-Hypaque梯度上离心后,将细胞悬液与99mTc-MIBI一起孵育,摄取情况以细胞内特异性保留的放射性百分比表示。通过微放射自显影评估示踪剂的细胞定位。27例患者中有22例在骨髓采样后一周内接受了99mTc-MIBI扫描。静脉注射555 MBq示踪剂10分钟后获取全身图像;使用半定量评分对99mTc-MIBI摄取的范围和强度进行分级。发现99mTc-MIBI的体外摄取与浆细胞浸润(Pearson相关系数r = 0.69,P < 0.0001)及体内评分(Spearman等级相关系数r = 0.60,P < 0.01)之间存在统计学显著相关性。在从2名健康供体获取的骨髓样本中未发现特异性示踪剂摄取。微放射自显影显示99mTc-MIBI定位于浸润骨髓的浆细胞内。因此,我们的研究结果表明,示踪剂在体外和体内的摄取程度与浸润浆细胞的百分比有关,这些浆细胞在其内部隔室中积累示踪剂。